Search research articles
Contact Us
Filters
Showing results (181-190 of 247) with videos related to
Page
of 25
Sort By:
Nature Medicine
|
May 13, 2022
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial
Ahmad Haidar, Leif Erik Lovblom, Nancy Cardinez, et al.
Diabetes Technology & Therapeutics
|
March 30, 2016
Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes
Geneviève Boulet, Elise M Halpern, Leif E Lovblom, et al.
The New England Journal of Medicine
|
July 1, 2010
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes
Richard M Bergenstal, William V Tamborlane, Andrew Ahmann, et al.
Diabetes Research and Clinical Practice
|
August 26, 2025
The rapidly increasing incidence of type 2 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: A decade of evidence from an international federated database
Matthew Anson, Alex E Henney, Harry Edwards, et al.
Diabetologia
|
October 5, 2014
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Skrtić, Gary K Yang, Bruce A Perkins, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 3, 2015
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes
Ahmad Haidar, Rémi Rabasa-Lhoret, Laurent Legault, et al.
Diabetologia
|
April 5, 2017
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Škrtić, Gary K Yang, Bruce A Perkins, et al.
Diabetes
|
November 28, 2023
Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 Diabetes
Luxcia Kugathasan, Vikas S Sridhar, Leif Erik Lovblom, et al.
Diabetes, Obesity & Metabolism
|
July 12, 2021
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes
Hongyan Liu, Vikas S Sridhar, Daniel Montemayor, et al.
Diabetes Care
|
March 6, 2019
Risk Factors for Kidney Disease in Type 1 Diabetes
Bruce A Perkins, Ionut Bebu, Ian H de Boer, et al.
Page
of 25
Search research articles
Search
Showing results (181-190 of 247) with videos related to
Sort By:
Page
of 25
Nature Medicine
|
May 13, 2022
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial
Ahmad Haidar, Leif Erik Lovblom, Nancy Cardinez, et al.
Diabetes Technology & Therapeutics
|
March 30, 2016
Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes
Geneviève Boulet, Elise M Halpern, Leif E Lovblom, et al.
The New England Journal of Medicine
|
July 1, 2010
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes
Richard M Bergenstal, William V Tamborlane, Andrew Ahmann, et al.
Diabetes Research and Clinical Practice
|
August 26, 2025
The rapidly increasing incidence of type 2 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: A decade of evidence from an international federated database
Matthew Anson, Alex E Henney, Harry Edwards, et al.
Diabetologia
|
October 5, 2014
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Skrtić, Gary K Yang, Bruce A Perkins, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 3, 2015
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes
Ahmad Haidar, Rémi Rabasa-Lhoret, Laurent Legault, et al.
Diabetologia
|
April 5, 2017
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Škrtić, Gary K Yang, Bruce A Perkins, et al.
Diabetes
|
November 28, 2023
Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 Diabetes
Luxcia Kugathasan, Vikas S Sridhar, Leif Erik Lovblom, et al.
Diabetes, Obesity & Metabolism
|
July 12, 2021
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes
Hongyan Liu, Vikas S Sridhar, Daniel Montemayor, et al.
Diabetes Care
|
March 6, 2019
Risk Factors for Kidney Disease in Type 1 Diabetes
Bruce A Perkins, Ionut Bebu, Ian H de Boer, et al.
Page
of 25